Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.

M. Toi, M. Gion, H. Saji, M. Asano, R. Dittadi, S. Gilberti, N. Locopo, G. Gasparini

Research output: Contribution to journalArticle

Abstract

Interleukin-12 (IL-12) is known to be a key cytokine for regulating immune response, but it is also known to provide some other biological function including inhibition of angiogenesis. We have determined using an enzymatic immunoassay the endogenous levels of IL-12 in 390 cytosols of primary breast cancers previously tested also for the angiogenic peptides, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP). The concentration of IL-12 ranged from 0 to 7.6 ng/mg protein, and 124 (31.8%) out of 390 cancers showed a detectable dose (>0.1 ng/ml). There was no statistical association of IL-12 levels with tumor size and menopausal status. IL-12 levels tended to be higher in the tumors of node-positive patients as compared to those of node-negative ones (t-test, p=0.082). In addition, IL-12 levels were inversely associated with hormone receptor status, particularly progesterone receptor expression (p=0.0013). There was a significant inverse association between IL-12 and TP concentration (p=0.0007). The proportion of tumors with detectable levels of IL-12 and low levels of either VEGF or TP was higher among the patients with node-negative as compared to those with node-positive disease. On the contrary, the proportion of tumors with no detectable IL-12 and high levels of either VEGF or TP was higher in node-positive versus node-negative cancers. In conclusion, our study evaluated the balance between pro-angiogenic factors (TP and VEGF) and IL-12, as a detectable naturally occurring inhibitor of angiogenesis, in the same series of node-negative and node-positive breast cancers. Further studies are warranted to investigate the biological and clinical significance of the co-determination of pro and contra angiogenic factors in human breast carcinoma.

Original languageEnglish
Pages (from-to)1169-1175
Number of pages7
JournalInternational Journal of Oncology
Volume15
Issue number6
Publication statusPublished - Dec 1999

Fingerprint

Angiogenesis Inducing Agents
Interleukin-12
Hormones
Thymidine Phosphorylase
Breast Neoplasms
Vascular Endothelial Growth Factor A
Neoplasms
Angiogenic Proteins
Angiogenesis Inhibitors
Progesterone Receptors
Immunoassay
Cytosol
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Toi, M., Gion, M., Saji, H., Asano, M., Dittadi, R., Gilberti, S., ... Gasparini, G. (1999). Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. International Journal of Oncology, 15(6), 1169-1175.

Endogenous interleukin-12 : relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. / Toi, M.; Gion, M.; Saji, H.; Asano, M.; Dittadi, R.; Gilberti, S.; Locopo, N.; Gasparini, G.

In: International Journal of Oncology, Vol. 15, No. 6, 12.1999, p. 1169-1175.

Research output: Contribution to journalArticle

Toi, M, Gion, M, Saji, H, Asano, M, Dittadi, R, Gilberti, S, Locopo, N & Gasparini, G 1999, 'Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.', International Journal of Oncology, vol. 15, no. 6, pp. 1169-1175.
Toi, M. ; Gion, M. ; Saji, H. ; Asano, M. ; Dittadi, R. ; Gilberti, S. ; Locopo, N. ; Gasparini, G. / Endogenous interleukin-12 : relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma. In: International Journal of Oncology. 1999 ; Vol. 15, No. 6. pp. 1169-1175.
@article{a014a2b974624702aa040676c9590da3,
title = "Endogenous interleukin-12: relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.",
abstract = "Interleukin-12 (IL-12) is known to be a key cytokine for regulating immune response, but it is also known to provide some other biological function including inhibition of angiogenesis. We have determined using an enzymatic immunoassay the endogenous levels of IL-12 in 390 cytosols of primary breast cancers previously tested also for the angiogenic peptides, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP). The concentration of IL-12 ranged from 0 to 7.6 ng/mg protein, and 124 (31.8{\%}) out of 390 cancers showed a detectable dose (>0.1 ng/ml). There was no statistical association of IL-12 levels with tumor size and menopausal status. IL-12 levels tended to be higher in the tumors of node-positive patients as compared to those of node-negative ones (t-test, p=0.082). In addition, IL-12 levels were inversely associated with hormone receptor status, particularly progesterone receptor expression (p=0.0013). There was a significant inverse association between IL-12 and TP concentration (p=0.0007). The proportion of tumors with detectable levels of IL-12 and low levels of either VEGF or TP was higher among the patients with node-negative as compared to those with node-positive disease. On the contrary, the proportion of tumors with no detectable IL-12 and high levels of either VEGF or TP was higher in node-positive versus node-negative cancers. In conclusion, our study evaluated the balance between pro-angiogenic factors (TP and VEGF) and IL-12, as a detectable naturally occurring inhibitor of angiogenesis, in the same series of node-negative and node-positive breast cancers. Further studies are warranted to investigate the biological and clinical significance of the co-determination of pro and contra angiogenic factors in human breast carcinoma.",
author = "M. Toi and M. Gion and H. Saji and M. Asano and R. Dittadi and S. Gilberti and N. Locopo and G. Gasparini",
year = "1999",
month = "12",
language = "English",
volume = "15",
pages = "1169--1175",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Endogenous interleukin-12

T2 - relationship with angiogenic factors, hormone receptors and nodal status in human breast carcinoma.

AU - Toi, M.

AU - Gion, M.

AU - Saji, H.

AU - Asano, M.

AU - Dittadi, R.

AU - Gilberti, S.

AU - Locopo, N.

AU - Gasparini, G.

PY - 1999/12

Y1 - 1999/12

N2 - Interleukin-12 (IL-12) is known to be a key cytokine for regulating immune response, but it is also known to provide some other biological function including inhibition of angiogenesis. We have determined using an enzymatic immunoassay the endogenous levels of IL-12 in 390 cytosols of primary breast cancers previously tested also for the angiogenic peptides, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP). The concentration of IL-12 ranged from 0 to 7.6 ng/mg protein, and 124 (31.8%) out of 390 cancers showed a detectable dose (>0.1 ng/ml). There was no statistical association of IL-12 levels with tumor size and menopausal status. IL-12 levels tended to be higher in the tumors of node-positive patients as compared to those of node-negative ones (t-test, p=0.082). In addition, IL-12 levels were inversely associated with hormone receptor status, particularly progesterone receptor expression (p=0.0013). There was a significant inverse association between IL-12 and TP concentration (p=0.0007). The proportion of tumors with detectable levels of IL-12 and low levels of either VEGF or TP was higher among the patients with node-negative as compared to those with node-positive disease. On the contrary, the proportion of tumors with no detectable IL-12 and high levels of either VEGF or TP was higher in node-positive versus node-negative cancers. In conclusion, our study evaluated the balance between pro-angiogenic factors (TP and VEGF) and IL-12, as a detectable naturally occurring inhibitor of angiogenesis, in the same series of node-negative and node-positive breast cancers. Further studies are warranted to investigate the biological and clinical significance of the co-determination of pro and contra angiogenic factors in human breast carcinoma.

AB - Interleukin-12 (IL-12) is known to be a key cytokine for regulating immune response, but it is also known to provide some other biological function including inhibition of angiogenesis. We have determined using an enzymatic immunoassay the endogenous levels of IL-12 in 390 cytosols of primary breast cancers previously tested also for the angiogenic peptides, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP). The concentration of IL-12 ranged from 0 to 7.6 ng/mg protein, and 124 (31.8%) out of 390 cancers showed a detectable dose (>0.1 ng/ml). There was no statistical association of IL-12 levels with tumor size and menopausal status. IL-12 levels tended to be higher in the tumors of node-positive patients as compared to those of node-negative ones (t-test, p=0.082). In addition, IL-12 levels were inversely associated with hormone receptor status, particularly progesterone receptor expression (p=0.0013). There was a significant inverse association between IL-12 and TP concentration (p=0.0007). The proportion of tumors with detectable levels of IL-12 and low levels of either VEGF or TP was higher among the patients with node-negative as compared to those with node-positive disease. On the contrary, the proportion of tumors with no detectable IL-12 and high levels of either VEGF or TP was higher in node-positive versus node-negative cancers. In conclusion, our study evaluated the balance between pro-angiogenic factors (TP and VEGF) and IL-12, as a detectable naturally occurring inhibitor of angiogenesis, in the same series of node-negative and node-positive breast cancers. Further studies are warranted to investigate the biological and clinical significance of the co-determination of pro and contra angiogenic factors in human breast carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0033449455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033449455&partnerID=8YFLogxK

M3 - Article

C2 - 10568824

AN - SCOPUS:0033449455

VL - 15

SP - 1169

EP - 1175

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -